Case Study

Trial Tokenization And Linking To Real World Data: Extending The Effectiveness And Safety Analysis Of A New Focal Seizure Treatment

Source: Datavant
Medical Data iStock-698677764

Recently, a biopharmaceutical company completed at 36 week Phase IV study of 175 patients across 40 trial sites to evaluate the effectiveness and safety of a recently approved anti-seizure medication as adjunctive therapy in focal seizure. Patient retention was the primary efficacy endpoint and seizure frequency was a secondary efficacy endpoint. The study also looked at tolerability. The initial study results showed that a substantial number of patients remained on therapy and experienced reduced seizure frequency. Read the available case study to find out more.

VIEW THE CASE STUDY!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: